Publication at First Faculty of Medicine |
2018
Abstract
The review article focuses on prognostic parameters of develepment of metastatic disease in castration resistant prostate cancer and on the latest results of studies in patients treated in the non-metastatic stage either with apalutamide (SPARTAN) or enzalutamide (PROSPER).